In fact, it induced a relatively modest but significative decrease in the Ka for NAG, illustrating the fact that NCG can be efficacious in CPS1D even when the CPS1 NAG site and affinity for the activator are not directly hampered. This evidence concerns the gene CPS1 and carbamoyl phosphate synthetase I deficiency disease.